Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding
Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved..
BACKGROUND & AIMS: Pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) is the treatment of choice for high-risk acute variceal bleeding (AVB; i.e., Child-Turcotte-Pugh [CTP] B8-9+active bleeding/C10-13). Nevertheless, some 'non-high-risk' patients have poor outcomes despite the combination of non-selective beta-blockers and endoscopic variceal ligation for secondary prophylaxis. We investigated prognostic factors for re-bleeding and mortality in 'non-high-risk' AVB to identify subgroups who may benefit from more potent treatments (i.e., TIPS) to prevent further decompensation and mortality.
METHODS: A total of 2,225 adults with cirrhosis and variceal bleeding were prospectively recruited at 34 centres between 2011-2015; for the purpose of this study, case definitions and information on prognostic indicators at index AVB and on day 5 were further refined in low-risk patients, of whom 581 (without failure to control bleeding or contraindications to TIPS) who were managed by non-selective beta-blockers/endoscopic variceal ligation, were finally included. Patients were followed for 1 year.
RESULTS: Overall, 90 patients (15%) re-bled and 70 (12%) patients died during follow-up. Using clinical routine data, no meaningful predictors of re-bleeding were identified. However, re-bleeding (included as a time-dependent co-variable) increased mortality, even after accounting for differences in patient characteristics (adjusted cause-specific hazard ratio: 2.57; 95% CI 1.43-4.62; p = 0.002). A nomogram including CTP, creatinine, and sodium measured at baseline accurately (concordance: 0.752) stratified the risk of death.
CONCLUSION: The majority of 'non-high-risk' patients with AVB have an excellent prognosis, if treated according to current recommendations. However, about one-fifth of patients, i.e. those with CTP ≥8 and/or high creatinine levels or hyponatremia, have a considerable risk of death within 1 year of the index bleed. Future clinical trials should investigate whether elective TIPS placement reduces mortality in these patients.
IMPACT AND IMPLICATIONS: Pre-emptive transjugular intrahepatic portosystemic shunt placement improves outcomes in high-risk acute variceal bleeding; nevertheless, some 'non-high-risk' patients have poor outcomes despite the combination of non-selective beta-blockers and endoscopic variceal ligation. This is the first large-scale study investigating prognostic factors for re-bleeding and mortality in 'non-high-risk' acute variceal bleeding. While no clinically meaningful predictors were identified for re-bleeding, we developed a nomogram integrating baseline Child-Turcotte-Pugh score, creatinine, and sodium to stratify mortality risk. Our study paves the way for future clinical trials evaluating whether elective transjugular intrahepatic portosystemic shunt placement improves outcomes in presumably 'non-high-risk' patients who are identified as being at increased risk of death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Journal of hepatology - 80(2024), 1 vom: 01. Jan., Seite 73-81 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
9NEZ333N27 |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jhep.2023.10.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363449132 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363449132 | ||
| 003 | DE-627 | ||
| 005 | 20240304232006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2023.10.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM363449132 | ||
| 035 | |a (NLM)37852414 | ||
| 035 | |a (PII)S0168-8278(23)05171-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Balcar, Lorenz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) is the treatment of choice for high-risk acute variceal bleeding (AVB; i.e., Child-Turcotte-Pugh [CTP] B8-9+active bleeding/C10-13). Nevertheless, some 'non-high-risk' patients have poor outcomes despite the combination of non-selective beta-blockers and endoscopic variceal ligation for secondary prophylaxis. We investigated prognostic factors for re-bleeding and mortality in 'non-high-risk' AVB to identify subgroups who may benefit from more potent treatments (i.e., TIPS) to prevent further decompensation and mortality | ||
| 520 | |a METHODS: A total of 2,225 adults with cirrhosis and variceal bleeding were prospectively recruited at 34 centres between 2011-2015; for the purpose of this study, case definitions and information on prognostic indicators at index AVB and on day 5 were further refined in low-risk patients, of whom 581 (without failure to control bleeding or contraindications to TIPS) who were managed by non-selective beta-blockers/endoscopic variceal ligation, were finally included. Patients were followed for 1 year | ||
| 520 | |a RESULTS: Overall, 90 patients (15%) re-bled and 70 (12%) patients died during follow-up. Using clinical routine data, no meaningful predictors of re-bleeding were identified. However, re-bleeding (included as a time-dependent co-variable) increased mortality, even after accounting for differences in patient characteristics (adjusted cause-specific hazard ratio: 2.57; 95% CI 1.43-4.62; p = 0.002). A nomogram including CTP, creatinine, and sodium measured at baseline accurately (concordance: 0.752) stratified the risk of death | ||
| 520 | |a CONCLUSION: The majority of 'non-high-risk' patients with AVB have an excellent prognosis, if treated according to current recommendations. However, about one-fifth of patients, i.e. those with CTP ≥8 and/or high creatinine levels or hyponatremia, have a considerable risk of death within 1 year of the index bleed. Future clinical trials should investigate whether elective TIPS placement reduces mortality in these patients | ||
| 520 | |a IMPACT AND IMPLICATIONS: Pre-emptive transjugular intrahepatic portosystemic shunt placement improves outcomes in high-risk acute variceal bleeding; nevertheless, some 'non-high-risk' patients have poor outcomes despite the combination of non-selective beta-blockers and endoscopic variceal ligation. This is the first large-scale study investigating prognostic factors for re-bleeding and mortality in 'non-high-risk' acute variceal bleeding. While no clinically meaningful predictors were identified for re-bleeding, we developed a nomogram integrating baseline Child-Turcotte-Pugh score, creatinine, and sodium to stratify mortality risk. Our study paves the way for future clinical trials evaluating whether elective transjugular intrahepatic portosystemic shunt placement improves outcomes in presumably 'non-high-risk' patients who are identified as being at increased risk of death | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cirrhosis | |
| 650 | 4 | |a TIPS | |
| 650 | 4 | |a decompensation | |
| 650 | 4 | |a endoscopic variceal ligation | |
| 650 | 4 | |a non-selective betablocker | |
| 650 | 7 | |a Creatinine |2 NLM | |
| 650 | 7 | |a AYI8EX34EU |2 NLM | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 700 | 1 | |a Mandorfer, Mattias |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Gea, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Procopet, Bogdan |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Elias Laurin |e verfasserin |4 aut | |
| 700 | 1 | |a Giráldez, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Amitrano, Lucio |e verfasserin |4 aut | |
| 700 | 1 | |a Villanueva, Candid |e verfasserin |4 aut | |
| 700 | 1 | |a Thabut, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Samaniego, Luis Ibáñez |e verfasserin |4 aut | |
| 700 | 1 | |a Silva-Junior, Gilberto |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Genescà, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Bureau, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Trebicka, Jonel |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera, Elba Llop |e verfasserin |4 aut | |
| 700 | 1 | |a Laleman, Wim |e verfasserin |4 aut | |
| 700 | 1 | |a Palazón Azorín, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Jose Castellote |e verfasserin |4 aut | |
| 700 | 1 | |a Gluud, Lise Lotte |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Carlos Noronha |e verfasserin |4 aut | |
| 700 | 1 | |a Cañete, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Ferlitsch, Arnulf |e verfasserin |4 aut | |
| 700 | 1 | |a Mundi, Jose Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Grønbæk, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez Guerra, Manuel Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Sassatelli, Romano |e verfasserin |4 aut | |
| 700 | 1 | |a Dell'Era, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Senzolo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Abraldes, Juan Gonzalez |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Gómez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Zipprich, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Casas, Meritxell |e verfasserin |4 aut | |
| 700 | 1 | |a Masnou, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Primignani, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Krag, Aleksander |e verfasserin |4 aut | |
| 700 | 1 | |a Nevens, Frederik |e verfasserin |4 aut | |
| 700 | 1 | |a Calleja, Jose Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Catalina, María Vega |e verfasserin |4 aut | |
| 700 | 1 | |a Albillos, Agustín |e verfasserin |4 aut | |
| 700 | 1 | |a Rudler, Marika |e verfasserin |4 aut | |
| 700 | 1 | |a Tapias, Edilmar Alvarado |e verfasserin |4 aut | |
| 700 | 1 | |a Guardascione, Maria Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Tantau, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarzer, Rémy |e verfasserin |4 aut | |
| 700 | 1 | |a Reiberger, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Laursen, Stig Borbjerg |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Gomez, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Cachero, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrarese, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Ripoll, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a La Mura, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a García-Pagán, Juan Carlos |e verfasserin |4 aut | |
| 700 | 0 | |a International Variceal Bleeding Observational Study Group by the Baveno Cooperation: an EASL consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hepatology |d 1993 |g 80(2024), 1 vom: 01. Jan., Seite 73-81 |w (DE-627)NLM012604372 |x 1600-0641 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:73-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhep.2023.10.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2024 |e 1 |b 01 |c 01 |h 73-81 | ||